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Background: Our previous research demonstrated that one subcutaneous injection of 17-Dimethylaminoethylamino-17-
demethoxygeldanamycin (17-DMAG) 24 hours (h) before irradiation (8.75 Gy) increased mouse survival by 75%. However,
the protective mechanism of 17-DMAG is currently unknown. The present study aimed to investigate whether oral
administration of 17-DMAG was also radioprotective and the potential role it may play in radioprotection.
Results: A single dose of orally pre-administered (24, 48, or 72 h) 17-DMAG (10 mg/kg) increased irradiated mouse
survival, reduced body weight loss, improved water consumption, and decreased facial dropsy, whereas orally
post-administered 17-DMAG failed. Additional oral doses of pre-treatment did not improve 30-day survival. The
protective effect of multiple pre-administrations (2−3 times) of 17-DMAG at 10 mg/kg was equal to the outcome of a
single pre-treatment. In 17-DMAG-pretreated mice, attenuation of bone marrow aplasia in femurs 30 days after
irradiation with recovered expressions of cluster of differentiation 34, 44 (CD34, CD44), and survivin in bone marrow
cells were observed. 17-DMAG also elevated serum granulocyte-colony stimulating factor (G-CSF), decreased serum
fms-related tyrosine kinase 3 ligand, and reduced white blood cell depletion. 17-DMAG ameliorated small intestinal
histological damage, promoted recovery of villus heights and intestinal crypts including stem cells, where increased
leucine-rich repeat-containing G-protein coupled receptor 5 (Lgr5) was found 30 days after irradiation.
Conclusions: 17-DMAG is a potential radioprotectant for bone marrow and small intestine that results in survival
improvement.
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17-dimethylamino-ethylamino-17-demethoxygeldanamycin
(17-DMAG) was a derivative of heat shock protein 90
(Hsp90) inhibitor geldanamycin [1,2]. Compared to
geldanamycin, 17-DMAG was greater water-soluble
and lower hepatotoxic [3], and was distributed more
rapidly in tissues. These advantages led to superior
clinical applications in human tumor therapy [4,5].
Human cancer studies [6,7] showed the mean half-life of
17-DMAG to be 22.3-24 h, which was much longer than* Correspondence: xinyue.lu.ctr@usuhs.edu
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reproduction in any medium, provided the orwhat has been previously observed in mice (69–88 min)
after an intravenous (i.v.) injection [8]. The drug was well
tolerated over periods of months of use even when
combined with other medical treatments such as radiation
therapy [4,9]. In vitro, 17-DMAG selectively killed human
tumor cells by chelating Hsp90 in its high-affinity conform-
ation, which existed only in cancer cells [10], and thereby
prevented mutant proteins from entering the nucleus to
trigger gene activation [11]. Because of the roles that Hsp90
played in key processes of tumor growth and development,
including induction and stabilization of growth factors and
other signals in transformed cells, angiogenesis, and
promotion of metastasis, Hsp90 understandably becameThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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to kill cancer cells.
Recent reports from our laboratory revealed that
17-DMAG protected human T-cells and normal healthy
peripheral blood mononuclear cells from γ-photon radiation
in vitro and ex vivo [12,13]. The protective effects were
associated with inhibiting inducible nitric oxide synthase
(iNOS)/caspase-3 cascade [12] and protein 53 (p53)
accumulations [13] to prevent apoptosis in irradiated
cells. Those results imply that Hsp90 inhibitors such
as 17-DMAG could be useful not only for cancer
therapy, but also for general radioprotection for normal
healthy tissues. 17-DMAG was, therefore, considered as a
candidate radioprotectant for total-body irradiation
countermeasure in vivo.
Total-body exposure to ionizing radiation in humans and
animals results in multiple organ injury and dysfunction.
Ionizing radiation injured hematopoietic, gastrointestinal,
or cerebrovascular systems depend on the total dose of
radiation received [14,15]. Safe and effective radioprotectors
were needed in the event of a radiological warfare or
accident, a nuclear terrorist attack, radiation therapy,
or prolonged space travel [14-18].
Our previous data demonstrated the potential of
17-DMAG as a radioprotector. A subcutaneous (s.c.)
injection of a single dose of 17-DMAG (25 mg/kg)
given to CD2F1 mice 24 h before a lethal dose of
gamma-radiation at 8.75 Gy (i.e., LD70/30, a dose
resulting in 70% of exposed population died within 30
days in a study [19]) improved mouse 30-day survival by
75 percentage points with a dose reduction factor (DRF)
of 1.2 [20]. However, oral administration of prophylactic
or therapeutic drugs is a most desirable and feasible
remedy of prevention or treatment in civilian and
military mass radiation casualties from a radiation accident,
or fist responders entering radiation contaminated areas. It
is, therefore, of great interest to determine whether orally
administered 17-DMAG was also radioprotective for sur-
vival, bone marrow, and small intestine. We hypothesized
that 17-DMAG given orally would provide radioprotection
but, possibly, at various levels of effectiveness in compari-
son to s.c. administration. In this study, we investigated the
radioprotective efficacy and possible underlying mecha-
nisms of 17-DMAG when it was administered orally in
mice prior to ionizing irradiation. This is the first report
that orally administered 17-DMAG provided prophylactic
reduction of ionizing radiation-induced lethality, bone
marrow damage, and small intestine injury in CD2F1 mice.
This radioprotective activity was demonstrated in (1)
partially preventing bone marrow cell damage with
the consequence of upregulated granulocyte-colony
stimulating factor (G-CSF) in serum, decreased fms-like
tyrosine kinase-3 (Flt-3) ligand in serum, and increased
survivin expression in bone marrow cells, which mayfurther promote bone marrow recovery, and (2) ameliorat-
ing the radiation-induced injury in small intestinal crypt
cells perhaps by increased leucine-rich repeat-containing
G-protein coupled receptor 5 (Lgr5)-positive crypt cells,
which may accelerate villus repairing and recovery 30 days
post-irradiation.
Results
Orally administered 17-DMAG prior to irradiation
increased mouse survival
Mice received a single oral dose of 5, 10, 25, or 75 mg/kg
17-DMAG 24 h before irradiation at 8.75 Gy (i.e. LD75/30).
In vehicle-treated mice, radiation-induced mortality started
at day 9 after irradiation and the 30-day survival was 33.5%
(Figure 1A). A single oral dose of 10 mg/kg 17-DMAG
protected 56.3% of mice from radiation-induced mortality.
The onset of mortality began at 11.6 d, 2.5 days later than
the vehicle-treated mice (11.625 ± 0.296 vs. 9.125 ± 0.5625,
p < 0.05, n = 4 repeated experiments) after irradiation and
prolonged the time to reach 50% survival (ST50) approxi-
mately by 8 days (≥25.25 ± 2.75 vs.17.00 ± 0.89, p < 0.05,
n = 4 repeated experiments). The dose-modifying factor
(DMF) [18] for oral administration of 17-DMAG 24 h
before irradiation (ratio of survival of animals treated with
17-DMAG to survival of the untreated animals) was
56.3/33.5 = 1.68. However, pretreatment with oral
doses of 5, 25, and 75 mg/kg did not improve mouse
30-day survival after irradiation (data not shown),
suggesting a narrow effective dose range via oral route in
irradiated CD2F1 mouse. 17-DMAG administered alone
up to 75 mg/kg without irradiation did not cause mortality
in sham animals (data not shown).
17-DMAG induced radioprotection for up to three days
before irradiation
The optimal oral administration time was determined
at the dose of 10 mg/kg of 17-DMAG as shown in
Figure 1A-D, oral administration of 17-DMAG 24, 48,
or 72 h before irradiation appeared to increase mouse
survival 20–25 percentage points above the corre-
sponding vehicle-treated group (p < 0.001). When the
same dose of 17-DMAG was given orally −1 h, how-
ever, no any survival improvement was found.
Multiple oral administrations of 17-DMAG induced the
same radioprotective efficacy as a single administration
Multiple oral administrations with 17-DMAG did not
further increase its radioprotective efficacy (Figure 2). The
percentage of survival in mice given a dose of 10 mg/kg
17-DMAG 2 or 3 times before irradiation was similar to
the survival percentage observed in mice treated with a
single dose of 17-DMAG (compared to Figure 1B). How-
















































































Figure 1 Orally administered 17-DMAG prior to irradiation increased mouse survival. (A) Administration of a single oral dose of 17-DMAG
(10 mg/kg) 24 h prior to irradiation at 8.75 Gy increased mouse 30-day survival by 20–25 % (p < 0.001, n = 16 mice per group) versus (vs.)
vehicle-treated irradiated (Veh/RI) animals. Furthermore, pretreatment of a single oral dose of 17-DMAG given 24 to 72 h before irradiation at 8.75 Gy
was still effective to improve survival. 17-DMAG (10 mg/kg) given 24 (B), 48 (C), or 72 h (D) before irradiation increased survival of irradiated mice by
20% above the vehicle-treated irradiated mice (p < 0.001, n = 16 per group). Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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of vehicle.
Oral administration of 17-DMAG after irradiation did not
increase survival
To determine if a single oral dose of 17-DMAG was
capable of producing therapeutic efficacy, mice received
10 mg/kg 17-DMAG orally, 1, 6, or 24 h after irradiation.
All oral administrations of 17-DMAG post-irradiation
failed to improve survival (data not shown).
17-DMAG attenuated body weight loss, promoted
recovery of reduced water consumption, and decreased
facial dropsy after irradiation
Based on the above results, mice received a single dose
of 10 mg/kg 17-DMAG 24 h prior to irradiation in the
following experiments to investigate changes in body
weight, water consumption, and facial dropsy. Irradiation
reduced body weights and water consumption [21], but did
not induce facial edema in B6D2F1/J mice. As shown in
Figure 3A, in CD2F1 mice, irradiation began to reduce the
body weight at day 5 and remained low. Irradiation mademice consume less water from day 1 through day 5. On day
6 the mice increased their water intake that returned to the
baseline on day 7 (Figure 3B). Irradiation insult also induced
facial dropsy, which began to occur approximately at day 10
(Figure 3C) and seemed to be one of animal moribund signs
in this strain. Compared to vehicle group, 17-DMAG ad-
ministration significantly prevented the radiation-induced
loss of body weights during days 15 to 30 (Figure 3A),
ameliorated a reduction of water consumption at days 1, 3,
5, and 6 (Figure 3B). It may be inferred that administration
of this drug provided some degree of protection from
gastrointestinal injury or dysfunction after irradiation. In
addition, an attenuation of facial dropsy was observed
at day 15 postirradiation in animals pretreated with
17-DMAG. At day 20 after irradiation, no significant differ-
ences of facial dropsy were observed between vehicle- and
17-DMAG-treated surviving mice (Figure 3C).
17-DMAG attenuated bone marrow damage after
irradiation
Mice that received a single oral dose of 10 mg/kg 17-DMAG

























































Figure 2 Multiple oral administrations of 17-DMAG induced a similar radioprotective efficacy to a single administration. (A) 17-DMAG
(10 mg/kg) or vehicle was given twice (2×) at −48 and −24 h, (B) given three times (3×) at −72, −48, and −24 h, or (C) given five times (5×) at
−120, −96, −72, −48, and −24 h prior to irradiation at 8.75 Gy (N = 16 mice per group). Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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elucidate the protective mechanism.
Bone marrow was examined for its morphological and
molecular alterations in surviving mice on the 30th day
postirradiation. Pathological changes in sections of femoral
bone marrows showed that irradiation reduced marrow
cellularity, thereby resulting in the absence of erythroid,
rare myeloid and megakaryocytic cells. Many fat vacuoles
appeared when stem cells and their lineages, especial mega-
karyocytes were depleted in the bone marrow (Figure 4C
vs. A and B). In contrast, microfoci were regenerated
partially (Figure 4D vs. C), megakaryocytes were restored
significantly (Figure 4E), and adipogenesis was reduced
after 17-DMAG administration (Figure 4F).
A separate experiment was performed in order to
determine the effects of 17-DMAG on the survival of
bone marrow cells in irradiated mice. Bone marrow cells
were collected from femora at days 3, 7 and 15 after
irradiation and total live bone marrow cells from each
murine femora were determined by trypan blue staining.
Gamma-irradiation induced cell death with a significant
reduction of total live cell numbers in femora at all three
time points. Although 17-DMAG did not significantly
improve the bone marrow cell viability at day 3 compared
to irradiated vehicle-treated animals, 17-DMAG did
markedly promote bone marrow cell viability at day
7 (17-DMAG/RI vs. vehicle/RI: 6.36 ± 1.75 × 105 vs.2.0 × 105 ± 2.48 × 104) and day 15 (8.26 ± 1.84 × 105
vs. 3.46 × 105 ± 2.91 × 104) after irradiation (Figure 5A).
Using a flow cytometric assay, it was determined that
17-DMAG increased bone marrow cell survival with a
greater percentage of 7-aminoactinomycin D (7AAD,
a death marker of cells) negative cells (Figure 5B left);
their average 7AAD-negative percentages in two groups of
17-DMAG/RI and Veh/RI mice (Figure 5B right) were
72.77 ± 7.17% and 44.2 ± 4.94% (p < 0.01, n = 3), respect-
ively, at day 15 after irradiation. The consistent results
from both methods indicate that 17-DMAG protects
bone marrow cells from irradiation, suggesting the
improved bone marrow cell viability may contribute
to increased 30-day survival in irradiated mice pretreated
with 17-DMAG.
17-DMAG attenuated radiation-induced reduction of
CD34 and CD44 expression in bone marrow cells
CD34 and CD44 are expressed in bone marrow cells. To
further verify the detrimental effects of irradiation on
bone marrow cells, CD34 and CD44 were measured
using Western blotting 30 days postirradiation. We
found that irradiation reduced the expression of both
CD34 and CD44, which was prevented by 17-DMAG
pre-treatment (Figure 5C). Although CD34 and 44 are
not specific markers, both are usually expressed in/on
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Figure 3 17-DMAG attenuated body weight loss and promoted recovery of reduced water consumption as well as facial dropsy. Mice
were orally administered with 10 mg/kg 17-DMAG or vehicle 24 h prior to irradiation at 8.75 Gy (N = 16 mice per group). Their body weights and
facial dropsy were monitored for 30 days. Water consumption was measured daily for the first 7 days. (A) Attenuation of body-weight loss during
days 15 to 30 after irradiation, * p = 0.03 vs. Veh/RI. Error bars indicate the standard error of the mean (SEM) for 5−16 mice per group at different
days. (B) Improvement of water consumption at days 1, 3, 5, and 6 during the first 7 days after irradiation, * p = 0.03 vs. Veh/RI group. Error bars
indicate the standard error of the SEM for 16 mice per group at different days. (C) Murine facial area at days 5, 10, 15, and 20 after irradiation. At day
10, * p < 0.01 vs. Veh/sham and 17-D/sham, and error bars indicate the SEM for 13−16 mice per group; at day 15, * p < 0.01 vs. Veh/sham, 17-D/sham,
and 17-D/RI; ** p < 0.001 vs. Veh/RI, error bars indicate the SEM for 9−16 mice per group. Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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CD34 and 44 after irradiation by 17-DMAG treatment
may reflect recovery of total bone marrow cells. Those
data reinforced the idea that 17-DMAG protects bone
marrow cells 30 days postirradiation.
17-DMAG increased survivin production in bone marrow
cells after irradiation
Survivin is one of several anti-apoptotic proteins. It is
over-produced in tumor cells and fetal tissue. Survivin
is, however, expressed in normal proliferating adult cells,
including human hematopoietic stem cells, T-lymphocytes,
and erythroid cells throughout their maturation. It mani-
fests its anti-apoptotic effects by inhibiting various caspases
and also uniquely promotes cell mitosis and proliferation
[22-24]. Inducible deletion of survivin leads to the bone
marrow ablation with widespread loss of hematopoietic
progenitors and rapid mortality [23].
To determine if 17-DMAG protected bone marrow cells
through upregulation of survivin expression, survivin pro-
tein production in bone marrow cells of mice 30 days
postirradiation was assessed using immunoblotting. Both17-DMAG alone and 17-DMAG combined with irradi-
ation upregulated survivin protein production in bone
marrow (Figure 6), but 17-DMAG increased survivin
significantly more than vehicle control at day 30 after
radiation. Average survivin expression in bone marrow
cells of 17-DMAG-treated irradiated animals was over
two-fold of its level in bone marrow of vehicle-treated
irradiated mice (Figure 6B).
17-DMAG upregulated serum G-CSF after irradiation
Because G-CSF stimulated growth of hematopoietic stem
cells in bone marrow [25], G-CSF in serum was assessed by
enzyme-linked immunosorbent assay (ELISA) and immuno-
blotting analysis 30 days postirradiation. Irradiation
(8.75 Gy) increased yet not significantly G-CSF con-
centration in serum, as compared to vehicle-treated
sham-operated groups. 17-DMAG (10 mg/kg at −24 h),
however, markedly enhanced the radiation-induced
G-CSF in animal serum at day 30 after irradiation.
The mean concentration of G-CSF in the irradiated
animals pre-treated with 17-DMAG vs. vehicle irradiated
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Figure 4 17-DMAG attenuated bone marrow damage after irradiation. Morphological alteration in femur bone marrows of mice pretreated
with (A) vehicle + sham, (B) 17-DMAG + sham, (C) vehicle + RI, and (D) 17-DMAG + RI 30 days after irradiation at 8.75 Gy. The images were from
epiphyseal ends with H & E staining, 20 ×magnification. A 100 μm scale bar was shown on the bottom of right panel D. Radiation induced vast
reduction of hematopoietic cellularity and replacement by adipocytes in bone marrow. However, (E) a significantly improved number of
megakaryocytes and (F) a significantly decreased numbers of adipocytes were found per field under microscopy (20 ×) in bone marrows of
17-DMAG-pretreated mice compared to those in vehicle-pretreated group 30 days after irradiation. * p < 0.001 vs. Veh/sham, 17-D/sham, and
17-D/RI; ** p < 0.01 vs. Veh/Sham, 17-D/sham, and Veh/RI group. Error bars indicate the SEM for at least 4–5 independent experiments. Veh:
vehicle; 17-D: 17-DMAG; RI: radiation injury.
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confirmed the observation obtained using the ELISA
method as well.
17-DMAG inhibited radiation-induced increase in Flt-3
ligand in serum and reversed radiation-induced white
blood cell (WBC) depletion in blood
Flt-3 ligand is a bio-indicator for bone marrow aplasia and
its release may be triggered by stem cell deficiency in the
bone marrow. Its concentration in serum is inversely
correlated to the bone marrow integrity [26,27].
In our study, Flt-3 ligand concentration was measured in
serum 30 days postirradiation. Irradiation notably increased
Flt-3 ligand concentrations (710.02 ± 36.94 pg/ml) in serum
of irradiated mice treated with vehicle (Figure 7B); whereas
17-DMAG significantly attenuated radiation-induced in-
crease in Flt-3 ligand concentrations (548.82 ± 28.83 pg/ml,
p < 0.05) in serum. Administration of 17-DMAG alone to
sham-treated mice did not alter the baseline of Flt-3
concentration in serum.
To determine the radioprotective effect of 17-
DMAG on circulating blood cells, peripheral blood
was collected and total WBCs were counted manually
at day 30. Although radiation reduced numbers of
WBCs (in 106 cells/ml: 1.09 ± 0.05 and 1.93 ± 0.06 of
vehicle- and 17-DMAG-pretreated irradiated samples vs.
3.88 ± 0.10 and 4.23 ± 0.23 of both sham controls),17-DMAG pretreatment increased the number of WBC
1.77 times greater (p < 0.001) than the vehicle pretreatment
after irradiation (Figure 7C).
17-DMAG had no significant effect on radiation-induced
erythropoietin (EPO) increase in serum
Because EPO produced by kidney and spleen is import-
ant for bone marrow cells [28], EPO in serum was
measured 30 days after irradiation. Irradiation induced
an increased EPO concentration in serum compared
to non-irradiated mice (Veh+ IR vs. Veh + sham: 175.84 ±
51.60 vs. 35.80 ± 7.40 pg/ml, p < 0.015). However, 17-DMAG
pre-administration did not alter the radiation-induced
increase in EPO concentrations compared to irradiated
mice pretreated with vehicle (data not shown).
17-DMAG ameliorated intestinal injury induced by
irradiation
To test the protective effect of 17-DMAG against radiation-
induced damage of the small intestine by pre-treatment with
this drug, histological analysis of the jejunum was performed
30 days post-irradiation. Small intestine of non-irradiated
mice showed a histological structure of the villus intestinalis
and crypts of Lieberkűhn with normal length of villus
and healthy crypt cells. In contrast, irradiation induced
severe pathological degeneration, which was still observed
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Figure 5 17-DMAG significantly promoted bone marrow cell viability after irradiation. Mice were administered with 17-DMAG or vehicle
24 h prior to irradiation at 9.25 Gy. (A) Bone marrow cell viability by trypan blue exclusion: total numbers of live bone marrow cells collected from
each femur bone of mouse at days 3, 7 or 15 after irradiation were measured by trypan blue staining. Irradiation reduced bone marrow cell viability
with a significant reduction of total live cell numbers in all three time points. 17-DMAG significantly increased bone marrow cell viability at days 7 and
15 after irradiation (N = 4–6 mice per group). At day 3, * p < 0.05 vs. Veh/sham, 17D/sham. At days 7 and 15, * p < 0.05 vs. Veh/sham, 17D/sham, and
17D/RI; ** p < 0.05 vs. Veh/sham, 17D/sham, and Veh/RI. Error bars indicate the SEM for 4–6 independent experiments at various time points. (B) Bone
marrow cell viability by flow cytometric assay: twenty thousands of bone marrow cells from each femur bone of mouse pre-treated with either
17-DMAG (left) or vehicle (right) at day 15 after irradiation were stained with 7-aminoactinomycin D (7AAD). 17-DMAG increased bone marrow cell
viability with a greater percentage of 7AAD-negative cells. Error bars indicate the SEM for at least three independent experiments. (C) Using Western
blotting, decreased CD34 and CD 44 protein were detected in bone marrow cells from femur bone of Veh/RI-mice at day 30 after irradiation at 8.75
Gy; 17-DMAG blocked the RI-induced suppression in both CD34 and 44 protein expression at day 30 after irradiation. * p < 0.05 vs. Veh/sham, 17-D
/sham, and 17D/RI. Error bars indicate the SEM for 4–5 independent experiments. Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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addition, decreased villus heights [29] and crypt numbers
[30] in the circumference of intestine were observed at
day 30 in surviving irradiated mice with vehicle pretreatment
(Figure 8E and F), whereas 17-DMAG pre-treatment
markedly improved the radiation-induced degenerative
changes in the small intestine. Increased villus lengths
(475.00 ± 15.99 vs. 337.53 ± 12.12 μm, p < 0.005), crypt
numbers per circumference (142.95 ± 12.79 vs. 102.00 ±
6.52, p < 0.0002), and recovered small intestinal morphologyin the irradiated mice pre-treated with 17-DMAG signifi-
cantly differed from vehicle-control mice (Figure 8).
17-DMAG increased small intestinal Lgr5 expression,
especially in crypt cells of irradiated mice
In order to verify whether 17-DMAG has protective
effect on small intestinal stem cells (ISC), Lgr5 expression
in ISC was measured. Lgr5 was identified as one of markers
of ISC. Lgr5-positive intestinal stem cells are crypt base






































Figure 6 17-DMAG increased survivin protein in bone marrow cells after irradiation. Bone marrow cells were collected from femur bones
and analyzed using Western blot for its survivin expression 30 days after irradiation at 8.75 Gy. (A) A representative Western blot of survivin. (B)
Densitometric quantitation of survivin protein.* p < 0.01 vs. Veh/sham, 17-D/sham, and 17D/RI groups; ** p < 0.001 vs. Veh/RI groups. Error bars
indicate the SEM for at least four independent experiments. Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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Irradiation at a high dose induced ISC damage or death
with a dramatic ablated Lgr5, which was observed 2 days
after irradiation in murine crypt cells [32]. Herein, irradi-
ation resulted in a decrease in the Lgr5 expression in small
intestine even at day 30 after irradiation. In comparison,
17-DMAG pretreatment enhanced intestinal Lgr5 level in
irradiated mice using western blot analysis (Figure 9A). The
density of Lgr5 in jejunum of 17-DMAG pretreated irradi-
ated mice was 3.34 fold (0.87 ± 0.18 vs. 0.26 ± 0.08, p < 0.01)
of that in vehicle-pretreated irradiated mice (Figure 9B).
Furthermore, the increased Lgr5 was located at the base of
the crypt cells using immunostaining and confocal laser
microscope (Figure 9C), indicating the presence of more
Lgr5-positive ISC in crypts.
Discussion
We investigated whether 17-DMAG attenuated radiation
injury in bone marrow cells and the small intestine,
including ISC. Although previous studies demonstratedsignificantly increased radiation sensitivity of tumor
cells in vivo [4] and in vitro [33] in the presence of
17-DMAG, the radiosensitivity of normal fibroblasts
was not altered by Hsp90 inhibition [34], suggesting
that the radiosensitization induced by 17-DMAG is
tumor-specific. Therefore, 17-DMAG could sensitize tumors
while protecting normal tissues from radiation-induced
injury or ischemia-induced infarction [34-36]. Our recent
studies [13] support the idea that 17-DMAG provides
protection for normal human peripheral blood mononuclear
cells from irradiation.
In the present study, orally administered 17-DMAG was
tested for radioprotection in CD2F1 mice. The results
showed that orally administered 17-DMAG as a single
dose of 10 mg/kg 24 h prior to 60Co γ-photon irradiation
increased mouse survival by 20–25 percentage points
more than corresponding controls. The radioprotective
effect of orally administered 17-DMAG is only prophylactic
and protective efficacy is not dose-dependent. Most import-





























































































































Figure 7 17-DMAG upregulated serum G-CSF, inhibited radiation-induced increases in serum Flt-3 ligand, and alleviated radiation-induced
WBC depletion in blood. Mice received a single oral administration of 17-DMAG (10 mg/kg) 24 h before irradiation at 8.75 Gy. Whole blood and
serum were collected 30 day after irradiation. (A) Serum G-CSF (pg/ml) was detected by ELISA: * p < 0.01 vs. Veh/sham, 17-D/sham, and Veh/RI groups,
error bars indicating the SEM for five independent experiments. (B) Measurement of serum Flt-3 ligand (pg/ml) by ELISA: * p < 0.001 vs. Veh/sham,
17-D/sham, and 17-D/RI groups; ** p < 0.001 vs. Veh/sham, 17-D/sham and Veh/RI, error bars indicating the SEM for six independent experiments. (C)
WBC counts (cells/ml): * p < 0.001 vs. Veh/sham, 17-D/sham, 17-D/RI groups; ** p < 0.001 vs. Veh/sham, 17-D/sham and Veh/RI groups, error bars also
indicating the SEM for six independent experiments. Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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approximately 8 days, in comparison with vehicle control
after irradiation. Meanwhile, given doses of 5, 25, and
75 mg/kg were not effective, suggesting that the oral
administration of 17-DMAG may have a narrow protective
window. It is not clear why the repeated dose of 10 mg/kg
administered to 2–3 times did not further increase radio-
protective efficacy in comparison of a single dose. The
effective dose, 10 mg/kg used in this study, is in agreement
with its administration in the mouse model of hemorrhagic
shock [37], in which orally administered 17-DMAG at a
single dose of 10 mg/kg reached the maximal effect,
whereas doses of 20, and 30 mg/kg did not further increase
the efficacy of preventing hemorrhagic injury.In this study, non-irradiated mice can tolerate an oral
dose of 17-DMAG up to 75 mg/kg without causing any
mortality 30 days after administration. This observation
is in agreement with that reported by Egorin [8]. However,
in irradiated mice, the optimal dose of orally administered
17-DMAG was 10 mg/kg. It is unclear why increased oral
doses to 25 or 75 mg/kg failed to improve 30-day survival
of irradiated animals. The oral doses of 25 and 75 mg/kg
(equal to 69.67 and 209.01 mg/m2/day in a mouse with
25 g of body weight, respectively) exceeded the maximum
tolerated dose (i.e., 16.1 mg/kg/day or 45 mg/m2/day) of
17-DMAG in mice [38]. Therefore, 17-DMAG at these
doses might lead to some potential tissue toxicity, especially
hepatotoxicity, liver dysfunction, and body weight loss [39].










































































Figure 8 17-DMAG ameliorated intestinal injury induced by irradiation. Mice received a single oral administration of 17-DMAG (10 mg/kg)
24 h before irradiation at 8.75 Gy. Intestinal tissues were collected 30 days after irradiation for histological assessment. Villus morphology and height were
assessed by H & E staining and observation under microscopy (10 ×) in jejunum of mice with (A) vehicle + sham, (B) 17-DMAG+ sham, (C) vehicle + RI,
and (D) 17-DMAG+ RI at day 30 after irradiation, n = 5–6 mice per group. A 200 μm scale bar was shown on the bottom of right panel D. Occurrence of
villus edema, decrease in villus heights, and ruptured villus tips were still present 30 days after the insult. 17-DMAG significantly improved recovery of
intestinal histological damage with (E) increased villus heights (* p < 0.002 vs. 17-D/RI, error bars indicating the SEM for five or six independent
experiments.) and (F) increased crypt numbers (* p < 0.01 vs. 17-D/RI, error bars indicating the SEM for five or six independent experiments) in transverse
sections of the full jejunal circumference in 17-D/ RI mice 30 days after irradiation. Veh: vehicle; 17-D: 17-DMAG; RI: radiation injury.
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17-DMAG at higher doses other than those administered
with 10 mg/kg (i.e., 27.87 mg/m2/day) from day 5 to
day 25 after irradiation (data not shown). Other laboratory
reported the selected nontoxic doses of oral 17-DMAG
at 7.5–15 mg/kg/day (i.e., 20.9–41.8 mg/m2/day) were
employed for an antitumor study in a carcinoma
mouse model [40]. Thus, it may explain why the orally
administered 17-DMAG at both high doses (may be toxic
to irradiated mice) was not radioprotective. We postulate
that a dose–response effect of 17-DMAG at doses less than
the maximum tolerated dose could still be feasible. We
also postulate that pre-administration of an oral dose of
10 mg/kg for 5 consecutive days could result in 17-DMAG
accumulating in liver, because it persists in this organ for
24 h after administration [8]. In liver and kidney tissues,
17-DMAG concentration was 10-40-fold greater than it in
plasma 10–1440 min after i.v. administration in mice
[41]. Therefore, the accumulated drug and its degradedproducts day by day in liver for 5 days might add even
more harm to hepatocytes and their functions that have
already been impaired by irradiation.
Orally administered 17-DMAG, however, produced a
lower survival efficacy than s.c. injected 17-DMAG
(56% oral vs. 95% s.c. [20]) 30 days after irradiation.
This discrepancy could be due to several factors.
Firstly, the route of drug administration and the vehicle
used were different. The optimal dose (10 mg/kg) for oral
administration differed from the dose (25 mg/kg) given
through s.c. injections. The vehicle used for orally admin-
istered 17-DMAG was 5% dextrose, whereas the vehicle
used for s.c. injected 17-DMAG was polyethylene glycol
400 (PEG-400). Secondly, 17-DMAG bioavailability was
100% by i.v., but only 50% by oral delivery in CD2F1 mice
[8] so that the drug bioavailability would be expected to
be higher by a s.c. injection than by an oral delivery.
Thirdly, although 17-DMAG was widely distributed to all
tissues, but the highest concentration of 17-DMAG was
ALgr-5
-actin
Veh+RI             17-DMAG+RI
















Green fluorescence: Lgr5; 20 X
C Veh+RI                           D  17-DMAG+RI  
Figure 9 17-DMAG upreguateded Lgr5 expression in crypt cells. (A) Lgr5 was detected with Western blot and its expression increased in
intestines of 17-DMAG-treated mice compared to vehicle-treated animals 30 days after irradiation at 8.75-Gy. (B) Densitometric quantitation of
Lgr5 protein.* p < 0.01 vs. Veh/RI group, error bars indicating the SEM for three or four independent experiments. Lgr5 (indicated by white
arrows) localizing at base cells of crypts in vehicle-pretreated (C) and 17-DMAG-pretreatd mice (D) was demonstrated using immune-staining
method and confocal microscope (20 ×) 30 days after irradiation and a 100 μm scale bar was shown on the bottom. N = 3–4 mice per group.
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initially and primarily absorbed by the gastrointestinal
tract, and quickly went into liver and was much accumu-
lated there, thereby limiting17-DMAG entering other tis-
sues and organs. While s.c. injected 17-DMAG in PEG
400 that increased the particle size was absorbed by sub-
cutaneous tissues and local vascular beds, and delivered to
various organs through circulation without prior drug
accumulation in liver. Subcutaneous tissues such as fat, in
fact, can store the drug that would be released gradually
because there is limited blood flow. Despite given 25 mg/kg
of 17-DMAG in PEG-400 via s.c. injection, being higher
than maximum tolerated dose per day, it was generally
absorbed more slowly, even taking more than 24–48 h into
blood. Thus, a greater radioprotective efficacy of s.c.
injected 17-DMAG than orally administered 17-DMAG
was observed.
We postulate that most of the orally administered
17-DMAG at 25 or 75 mg/kg might have been accumu-
lated, metabolized, and degraded in the livers of sham
animals. These processes would be critical to eliminate the
drug and its degraded products from the body, otherwise
producing potential harmful side effects or tissue toxicity in
48–72 h. In irradiated mice, the livers were incapable or
limitable of performing detoxification due to impairment
caused from the lethal whole-body irradiation. As a result
of this failure to detoxify, the pharmacologic effectsof 17-DMAG at high doses decrease or become detrimen-
tal. Only a nontoxic oral dose of 17-DMAG at 10 mg/kg
enable to retain radioprotection.
We noticed that repeated 17-DMAG administrations
at 10 mg/kg failed to further improve the mouse survival
after irradiation. We hypothesize that it is possible due
to degraded products of 17-DMAG accumulating in an
impaired liver caused by irradiation. This accumulation of
degraded products resulted in toxicity to the irradiated
mice. The same explanation may also explain why orally
administered 17-DMAG for 5 consecutive days before
irradiation failed to improve the mouse survival after
irradiation.
Post-treatment with 17-DMAG also failed to improve
survival after irradiation, due to radiation-induced DNA
double strand breaks (DSB) and p53 phosphorylation,
which occurred within 1 h after irradiation. Those events
were then followed by sequential activations of signal
transduction pathways leading to cell death and multiple
organ dysfunction and failure. We have reported that
pretreatment of human T cells with 17-DMAG was
effective in preventing DSB and p53 phosphorylation
by blocking p53 interaction with Hsp 90, and p53
gene knockout cells were also resistant to irradiation
[13]. This likely explains why in this presented study pre-
treatment with 17-DMAG is effective. Post-treatment with
17-DMAG probably would be too late to stop DSB
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post-treatment with the drug is ineffective.
Radiation significantly reduced body weight and water
consumption in CD2F1 mice (Figure 3); these observations
agree with those in B6D2F1/J mice [21]. Radiation-induced
facial dropsy was found in CD2F1 mice [42], C57BL/6
mice, and iNOS knockout mice, but not B6D2F1/J mice
(data not shown), suggesting this observation could be
strain-specific. It is highly likely that 17-DMAG inhibition
on radiation-induced facial edema may involve in its
activity of anti-inflammation, but more experiments
will be necessary.
Radiation significantly depleted bone marrow cells and
induced adipose vacuole appearance (Figure 4C). In
17-DMAG-treated mice, amelioration of bone marrow
cell depletion, accelerated recovery of the cellularity,
and reduced adipogenesis of bone marrow (Figure 4D)
were observed accompanied by upregulation of CD34 and
CD44 expression (Figure 5C), indicating that 17-DMAG
could protect bone marrow cells of 30-day surviving mice
after irradiation. The view is further reinforced by increased
numbers of live bone marrow cells at days 7 and 15 and
elevated 7AAD-negative percentage of bone marrow
cells at day 15. However, how 17-DMAG exerting its
radioprotection on bone marrow cells remains unknown.
Survivin is normally bound to Hsp90 in the cytoplasm
[22]. It is reported that cultured SW480 cell exposed to
a 4-Gy irradiation [43], the nuclear survivin was linked
to DNA double-strand-break repair by interaction with
members of the repair pathway. This view is supported
by a study using normal healthy human peripheral blood
mononuclear cells, in which 17-DMAG inhibited radiation-
induced increases in γ-H2AX, a biomarker of DSB [13].
Although irradiation increased the survivin protein level
at day 30 after irradiation, we think this increase is a
self-defensive response which is too late to alleviate
the mortality. We postulate that 17-DMAG inhibits Hsp90
resulting in the release of survivin from Hsp90 and then
survivin ready for involving in the process of repairing the
radiation-induced DSB.
Our survivin data agree with findings from another
laboratory [44], in which 17-DMAG (0.1–1 μg/ml) alone
elevated survivin production in vitro and rendered the cells
insensitive to apoptosis. Survivin is anti-apoptotic by
inhibiting various caspases [22,24]. Our laboratory reported
that 17-DMAG inhibited caspase-3 and -9, leading to an in-
hibition of apoptosis [12,37]. It is plausible that 17-DMAG
increased mouse survival after irradiation by activating the
survivin pathway that may regulate β-catenin, p53,
NF-κB, and Stat3 multiple signalings [45] and caspase-3
and -7 [24]. Further investigation of survivin regulation by
17-DMAG is warranted.
Moreover, the 17-DMAG ameliorating bone marrow
damage induced by irradiation correlates with the reductionof Flt-3 ligand concentrations in serum (Figure 7B). The
serum level of Flt-3 ligand has been suggested as a bio-
marker of radiation injury to bone marrow and a surrogate
for the extent of damage to hematopoietic progenitor cells
in bone marrow after ionizing irradiation [46-48]. Thus,
the reduction of radiation-induced higher Flt-3 ligand
concentrations is another indirect evidence to support
the radioprotection of bone marrow cells by 17-DMAG.
Our result on Flt-3 ligand concentrations is consistent
with that in another report [46] that the concentration of
serum Flt-3 ligand is reversely correlated with WBC
counts in peripheral blood.
17-DMAG attenuated the radiation-induced WBC
depletion (Figure 7C), which correlated with G-CSF
increases in the presence of 17-DMAG (Figure 7A).
G-CSF acts at all stages of neutrophil development, specif-
ically increasing the proliferation and differentiation of
neutrophils from committed progenitors [49], enhancing
survival and function of mature neutrophils [50,51]. G-CSF
is a cytokine and a growth factor, which possesses radio-
protective properties [52,53] by stimulating growth, differ-
entiation and prevention of apoptosis of progenitor cells.
Like 17-DMAG, pre-administration of alpha-tocopherol
succinate [54,55] and post-treatment with meloxicam [56]
or 5-androstenediol [57] increased serum G-CSF concen-
trations within 4–24 h after injections. Alpha-tocopherol
succinate induced a peak level of G-CSF within 24 h and a
rapid fall 36 h after s.c. administration. Our other
data from irradiated CD2F1 mice pre-treated s.c. with
17-DMAG also indicated that 17-DMAG enhanced
serum G-CSF concentration as early as 4 h and lasted
up to day 2, 10, and 15 after irradiation compared with
the vehicle group (Lu et al., unpublished data). These data
suggest that 17-DMAG, like other radioprotectant such as
alpha-tocopherol succinate, confers radioprotection by
inducing high levels of G-CSF. Other studies indicated that
G-CSF not only enhanced the production of hematopoietic
progenitor cells in bone marrow but also mobilized those
primitive progenitors from the hematopoietic tissue into the
circulation [58,59]. Therefore, 17-DMAG administration
increased numbers of WBC probably mediated by the
increasing G-CSF 30 days postirradiation. The present study
may offer a new insight on regulation of survivin and
G-CSF by 17-DMAG. However, the possibility of increased
G-CSF concentrations being a consequence of hematopoietic
recovery cannot be excluded.
It is known that 17-DMAG inhibits activation of the
iNOS pathway in vitro [37] and in vivo [20], and the p53
pathway ex vivo [13]. Further studies should explore
the inter-relationship among iNOS, p53, and survivin
pathways and the regulation of G-CSF.
Radiation-induced gastrointestinal syndrome (RIGS)
results from a combination of direct cytocidal effects on
intestinal crypt and endothelial cells and subsequent loss
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imbalance, diarrhea, weight loss, infection, dysfunction, and
final mortality. Stem cells located at the base of the crypt
undergo rapid apoptosis or stop dividing temporarily or
permanently after irradiation. Therefore, RIGS is due in
part to the killing of clonogenic crypt cells with eventual
depopulation of the intestinal villi [60].
17-DMAG attenuated the pathological alteration in
villi 30 days postirradiation. Oral administration of
17-DMAG (10 mg/kg) decreased mucosal atrophy,
edema and ulceration, increased the number of crypts
where ISC are located, and more importantly, upregulated
expression of Lgr5 (a molecular marker of ISC in intestinal
crypts). The results agree with the findings in hemorrhaged
jejunum [37], suggesting that 17-DMAG prevents the
radiation-induced structural injury in small intestine, body
weight loss, and facial edema, further improves survival of
irradiated mice.
Since in hemorrhaged small intestine, 17-DMAG
diminished hemorrhage-induced small intestine injury
by elevating Bcl-2 protein and inhibiting iNOS pathway,
TNF-α production, and caspase-3 activation [37], the
possibility of 17-DMAG exerting its actions on these
factors to ameliorate the radiation-induced gastrointestinal
injury cannot be excluded. More studies in this regard are
ongoing.
Conclusion
A single dose of orally administered 17-DMAG (10 mg/kg)
as a prophylactic measure prior to irradiation was effective
to increase mouse 30-day survival by protecting bone mar-
row and small intestine from radiation injury. The protect-
ive effects of pre-administered 17-DMAG were associated
with (1) increased expression of survivin, CD34, CD44 in
bone marrow and G-CSF in serum, which were correlated
with attenuated bone marrow injury and WBC loss and
were confirmed by the decreased Flt-3 ligand concentration
in circulation; (2) up-regulated Lgr5 expression and
Lgr5-positive stem cells in intestinal crypts, which
promoted intestinal epithelial repairing, self-renewing
and body weight recovery from irradiation-induced
injury. Taken together, our results suggest that 17-DMAG
appears to be an effective prophylactic radioprotectant
in bone marrow cells and in intestinal crypt cells including
intestinal stem cells, which contributes to enhanced survival.
Materials and methods
Animals
Male CD2F1 mice were purchased from Harlan Laboratories
(Dublin, VA, USA) and used at age of 10 to 12 weeks
at the time of irradiation. The mice were housed in
groups of four in polycarbonate microisolator cages
(11.5 × 7.5 × 5 in.) with filter tops on autoclaved rodent
hardwood bedding. Animal rooms were maintained at21 ± 2°C, 50% ± 10% humidity, and 12-h light/dark cycle.
All facilities were accredited by the Association for Assess-
ment and Accreditation of Laboratory Animal Care Inter-
national. Rodent food (Harlan Teklad Rodent Diet 8604)
and water were freely available for mice. All handling
procedures were performed in compliance with guide-
lines from the National Research Council, and were
approved by the Institutional Animal Care and Use
Committee (IACUC) of the AFRRI.17-DMAG preparation and oral administration
17-DMAG (LC Laboratories, Woburn, MA, USA) was
prepared as previously described [37]. Briefly, 17-DMAG
was freshly solubilized in 5% Dextrose (Baxter Healthcare,
Deerfield, IL, USA) on the day of the experiment. The
drug was orally administered to mice at (1) a single dose
of 5, 10, 25, or 75 mg/kg in a volume of 0.2 ml 24 h before
irradiation; (2) a single dose of 10 mg/kg 1, 24, 48, or 72 h
prior to irradiation; (3) a single dose of 10 mg/kg 1, 6, or
24 h after irradiation; and (4) multiple doses of 10 mg/kg
120, 96, 72, 48 and 24 h before irradiation. Vehicle groups
were orally fed the same volume of 5% Dextrose.Irradiation
Mice were restrained in well-ventilated acrylic irradiation
boxes. Mice were given a dose of 8.75 Gy 60Co γ photons
at a dose rate of 0.6 Gy/min bilaterally in the AFRRI 60Co
Irradiation Facility. The uniformity of the field in the used
part of the rack was ± 1%. Control (sham) animals were
placed into the acrylic radiation boxes but were not
irradiated. The total tissue dose of radiation received
was measured at the level of the abdominal core. An
alanine electron-spin-resonance (ESR) dosimetry system
(American Society for Testing and Materials, Standard E
1607) was used to measure dose rates (to water) in the
cores of acrylic mouse phantoms. To simulate a mouse,
the phantoms were three inches in length and one
inch in diameter. For field mapping, all exposure rack
compartments contained phantoms, and alternate phan-
toms contained alanine dosimeters. The ESR signals were
measured using a calibration curve based on the standard
calibration dosimeters (National Institute of Standards
and Technology (NIST), Gaithersburg, MD, USA). The
overall uncertainty in the doses given to the calibration
dosimeters at NIST was approximately 1.8% at 2 standard
deviations. The accuracy of the calibration curve was
verified by parallel measurements of doses to selected
dosimeters at AFRRI and the National Physical Laboratory,
Middlesex, England, UK. Corrections were applied to
the dose rates in phantoms for the decay of 60Co and
differences in the mass energy-absorption coefficients
for water and soft tissue [61]. The day of irradiation
was considered day 0.
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facial dropsy
Sixteen mice were randomly assigned to each group.
Experimental groups included: (1) 5% Dextrose vehicle +
sham (Veh/sham), (2) 17-DMAG+ sham (17-D/sham), (3)
5% Dextrose vehicle + radiation injury (Veh/RI), and (4)
17-DMAG+ radiation injury (17-D/RI). After irradiation,
mice were returned to their home cages. Water consump-
tion was measured with graduated water bottles daily for
the first 7 days. Mouse survival, body weight, and facial
dropsy were monitored for 30 days post-irradiation. At
day 30, the surviving mice were euthanized and their
bloods, intestines and femurs were collected for analysis.Histological examination, bone marrow myeloid cell
viability, and cell phenotype analysis
One femur from each surviving mouse 30 days after
irradiation was fixed in 10% formalin for at least 24 h.
All samples were embedded with paraffin and sectioned
longitudinally for haematoxylin & eosin (H & E) staining.
The stained slides were examined at 20 ×magnification
under microscope (Olympus BX-61, Olympus, Japan).
Bone marrow cells were flushed from the other femur of
each surviving mouse 30 days after irradiation. After two
washes with phosphate buffered saline (PBS) solution,
cells were lysed by using lysis buffer and their proteins
were extracted following a commercial extraction method
(Pierce Protein Research, Rockford, IL, USA). For investi-
gating effect of 17-DMAG on bone marrow after irradi-
ation, bone marrow cells were also collected from mouse
femora at 3, 7 and 15 days after irradiation in a separate
experiment. After erythrocytes were lysed by red blood cell
lysis buffer (BioLegend San Diego, CA, USA), total bone
marrow cell viability from each mouse was assayed by
trypan blue staining [12]. For bone marrow cells from the
mice at day 15 after irradiation, cells also were labeled with
7AAD, a death marker of cells and their cell viabilities were
analyzed by flow cytometry using BD FACSCalibur
(BD Biosciences, San Jose, CA, USA). Cells were gated for
7AAD-positive cells and negative live cells. All antibodies
and dyes were purchased from BD Biosciences.Intestinal histological and immunohistochemical
assessments
Small intestine was harvested after 30-day survival for
intestinal protein expression or morphological analysis.
The distal jejunum and proximal ileum were fixed for
histology in 10% formalin with PBS. Paraffin embedded
gut tissues were sectioned and stained with H & E.
Nanozoomer virtual microscopy (Hamamatsu Photonics,
Hamamatsu, Japan) was used for measurement of the villus
height and the count of crypt numbers. A minimum of 10
well-oriented villi per tissue section (at least 5 sections fromeach gut specimen) was measured and crypt numbers were
counted in all 5 sections of each specimen.
Frozen slides of ileum were prepared and immunostained,
following a previous published method [62] for expression
and localization of Lgr5 in small intestine. Briefly, after
fixing and blocking procedure, slides were incubated with
primary antibodies, goat anti-Lgr5 IgG (Genway, SanDiego,
CA, USA) 1:100 dilution for 60 min. Slides were incubated
with secondary antibodies, donkey anti-goat IgG-Alexa
Fluor 488 (Invitrogen, Carlsbad, CA, USA) for 1 h. Finally,
slides were mounted with ProLong Gold Antifade,
counterstained with DAPI (4’,6’-diamidino-2-phenylindole;
Invitrogen, Carlsbad, CA, USA), and observed under
a confocal laser scanning microscope (Zeiss LSM710,
Carl Zeiss MicroImaging, Thornwood, NY, USA).Western blot
Proteins in lysates of bone marrow and gut tissues were
separated by 4-12% Bis-tris gel electrophoresis and trans-
ferred onto a nitrocellulose membrane according to a stand-
ard technique for antibody detection of proteins. Primary
antibodies against mouse G-CSF (BD Pharmingen, San
Diego, CA, USA), CD44 (BioLegend, San Diego, CA, USA),
CD34 (Santa Cruz Biotechnology, Santa Cruz, CA, USA),
Lgr5 (Genway, SanDiego, CA, USA), survivin (Millipore,
Temecula, CA, USA), and β-actin (Sigma, St. Louis, MO,
USA) were used in immunoblotting assays, respectively.Enzyme-linked immunosorbent assay
Murine serum levels of EPO, G-CSF, and Flt-3 ligand
were measured by ELISA (R&D Systems, Minneapolis,
MN, USA) according to the manufacturer’s protocols.White blood cell counts
Blood was collected by cardiac puncture from mice anes-
thetized with isoflurane inhalation and placed promptly in
an ethylenediaminetetraacetic acid (EDTA)-containing tube
for blood cell counts and a regular eppendorf tube for
serum separation. Red blood cells in the EDTA-containing
tube were lysed by RBC lysis buffer (BioLegend San Diego,
CA, USA), and the remaining leukocytes were washed in
1% ammonium oxalate solution. The total number of
leukocytes in 10 μl of blood was counted manually in
a hemocytometer.Statistical analysis
The data of 30-day survival of mice were analyzed using
Two-way analysis of variance (ANOVA). For parametric
data, differences among or between groups were com-
pared by ANOVA and Student’s t-test, respectively, with
significance at p < 0.05. Results of parametric data were
presented as means ± standard errors.
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7AAD: 7-aminoactinomycin D; 17-DMAG: 17-dimethylamino-ethylamino-17-
demethoxygeldanamycin; CBC: Crypt base columnar; CD34, CD44: Cluster of
differentiation 34, 44; DMF: Dose-modifying factor; DRF: Dose reduction
factor; DSB: DNA double strand breaks; EPO: Erythropoietin; Flt-3: fms-like
tyrosine kinase-3; G-CSF: Granulocyte-colony stimulating factor; Hsp90: Heat
shock protein 90; iNOS: Inducible nitric oxide synthase; ISC: Intestinal stem
cells; i.v.: Intravenous; LD70/30: A dose to result in 70 percent of an exposed
population died within 30 days; Lgr5: Leucine-rich repeat-containing
G-protein coupled receptor 5; RBC: Red blood cell; s.c.: Subcutaneous; Veh/
sham: Vehicle + sham; ST50: Median survival time; 17-D/sham: 17-DMAG + sham;
Veh/RI: Vehicle + radiation injury; 17-D/RI: 17-DMAG + radiation injury;
WBC: White blood cell.
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